Financials: Introgen Therapeutics, Inc. (INGNQ.PK)
INGNQ.PK on USA Pink Sheets
0.01USD
9 Feb 2010
0.01USD
9 Feb 2010
Price Change (% chg)
$0.00 (+0.00%)
$0.00 (+0.00%)
Prev Close
$0.01
$0.01
Open
--
--
Day's High
$0.01
$0.01
Day's Low
$0.01
$0.01
Volume
19,000
19,000
Avg. Vol
7,642
7,642
52-wk High
$0.09
$0.09
52-wk Low
$0.01
$0.01
Revenue
| Periods | 2006 | 2007 | 2008 |
|---|---|---|---|
| September | 0.225 | 0.322 | 0.186 |
| December | 0.098 | 0.082 | 0.121 |
| March | 0.733 | 0.139 | 0.331 |
| June | 0.095 | 0.468 | |
| Totals | 1.151 | 1.011 |
Note: Units in Millions of U.S. Dollars
Earnings Per Share
| Periods | 2006 | 2007 | 2008 |
|---|---|---|---|
| September | -0.22106 | -0.12867 | -0.05456 |
| December | -0.20667 | -0.17691 | -0.14418 |
| March | -0.15406 | -0.17211 | -0.13552 |
| June | -0.18466 | -0.2173 | |
| Totals | -0.76611 | -0.69524 |
Note: Units in U.S. Dollars
Consensus Estimates Analysis
No consensus analysis data available.
Sales and Earnings Figures in U.S. Dollars (USD)
Valuation Ratios
| Company | Industry | Sector | S&P 500 | |
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 11.50 | 3.76 | 14.59 |
| P/E High - Last 5 Yrs. | NA | 6.38 | 1.59 | 16.18 |
| P/E Low - Last 5 Yrs. | NA | 2.77 | 0.55 | 4.36 |
| Beta | -- | 0.65 | 0.65 | 1.33 |
| Price to Sales (TTM) | 0.36 | 29.11 | 1.22 | 2.01 |
| Price to Book (MRQ) | -- | 3.61 | 1.99 | 2.58 |
| Price to Tangible Book (MRQ) | -- | 18.26 | 3.19 | 5.66 |
| Price to Cash Flow (TTM) | -- | 6.76 | 2.07 | 7.12 |
| Price to Free Cash Flow (TTM) | -- | 15.28 | 24.92 | 12.79 |
| % Owned Institutions | -- | -- | -- | -- |
Dividends
| Company | Industry | Sector | S&P 500 | |
|---|---|---|---|---|
| Dividend Yield | NA | 0.02 | 0.29 | 1.71 |
| Dividend Yield - 5 Year Avg. | 0.00 | 0.02 | 1.60 | 2.35 |
| Dividend 5 Year Growth Rate | -- | 0.31 | 15.63 | -5.31 |
| Payout Ratio(TTM) | -- | 0.75 | 4.46 | 24.71 |
Growth Rates
| Company | Industry | Sector | S&P 500 | |
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 138.13 | 78.04 | 6.84 | 10.73 |
| Sales (TTM) vs TTM 1 Yr. Ago | 73.35 | 20.75 | 1.90 | -4.74 |
| Sales - 5 Yr. Growth Rate | -2.93 | 20.82 | 8.05 | 7.42 |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 21.26 | 95.58 | 142.38 | 98.28 |
| EPS (TTM) vs TTM 1 Yr. Ago | 16.73 | -- | -- | -- |
| EPS - 5 Yr. Growth Rate | -- | 16.65 | 5.61 | 8.85 |
| Capital Spending - 5 Yr. Growth Rate | 18.94 | 3.87 | 6.95 | 5.91 |
Financial Strength
| Company | Industry | Sector | S&P 500 | |
|---|---|---|---|---|
| Quick Ratio (MRQ) | 1.04 | 5.80 | 2.57 | 0.81 |
| Current Ratio (MRQ) | 1.04 | 6.27 | 3.05 | 0.95 |
| LT Debt to Equity (MRQ) | -- | 22.84 | 25.13 | 127.01 |
| Total Debt to Equity (MRQ) | -- | 26.92 | 32.96 | 179.52 |
| Interest Coverage (TTM) | -- | 46.19 | 3.69 | 11.83 |
Profitability Ratios
| Company | Industry | Sector | S&P 500 | |
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 41.84 | 12.78 | 31.64 |
| Gross Margin - 5 Yr. Avg. | -- | 56.10 | 56.69 | 29.11 |
| EBITD Margin (TTM) | -2,575.14 | -- | -- | -- |
| EBITD - 5 Yr. Avg | -2,070.69 | -149.46 | 16.23 | 15.13 |
| Operating Margin (TTM) | -2,667.18 | -392.08 | -4.90 | -- |
| Operating Margin - 5 Yr. Avg. | -2,209.41 | -173.30 | 12.24 | 17.30 |
| Pre-Tax Margin (TTM) | -2,193.76 | -395.84 | -4.88 | 12.47 |
| Pre-Tax Margin - 5 Yr. Avg. | -2,101.71 | -166.39 | 14.23 | 16.97 |
| Net Profit Margin (TTM) | -2,193.76 | -397.60 | -5.71 | 9.80 |
| Net Profit Margin - 5 Yr. Avg. | -2,101.71 | -168.72 | 7.73 | 12.33 |
| Effective Tax Rate (TTM) | -- | 8.43 | 3.58 | 14.83 |
| Effecitve Tax Rate - 5 Yr. Avg. | -- | 25.73 | 34.40 | 26.46 |
Efficiency
| Company | Industry | Sector | S&P 500 | |
|---|---|---|---|---|
| Revenue/Employee (TTM) | 13,825 | 244,231 | 1,282,917 | 299,091 |
| Net Income/Employee (TTM) | -303,288 | -162,605 | 213,959 | 26,863 |
| Receivable Turnover (TTM) | -- | 3.23 | 0.89 | 8.07 |
| Inventory Turnover (TTM) | -- | 1.33 | 0.64 | 5.03 |
| Asset Turnover (TTM) | 0.04 | 0.26 | 0.12 | 0.44 |
Management Effectiveness
| Company | Industry | Sector | S&P 500 | |
|---|---|---|---|---|
| Return on Assets (TTM) | -90.19 | 1.57 | 1.78 | 4.25 |
| Return on Assets - 5 Yr. Avg. | -58.25 | -3.15 | 6.74 | 4.83 |
| Return on Investment (TTM) | -117.92 | 1.25 | 2.30 | 5.67 |
| Return on Investment - 5 Yr. Avg. | -68.93 | -3.49 | 8.69 | 6.33 |
| Return on Equity (TTM) | -181.20 | 2.09 | 2.82 | 12.56 |
| Return on Equity - 5 Yr. Avg. | -88.75 | -5.89 | 10.04 | 12.84 |
| 1 Year | 3 Years | 5 Years | |
|---|---|---|---|
| Sales % | -12.16 | -17.61 | -2.93 |
| EPS % | 9.25 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Introgen Therapeutics, Inc.
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 12.42% |
| # of Holders: | 5 |
| Total Shares Held: | 5,482,380 |
| 3 Mo. Net Change: | 0 |
| # New Positions: | 0 |
| # Closed Positions: | 0 |
| # Increased Positions: | 0 |
| # Reduced Positions: | 0 |
| # Net Buyers: | 0 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
